Valeant Pharmaceuticals International Inc (VRX): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Valeant Pharmaceuticals International ( VRX) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 1.8%. By the end of trading, Valeant Pharmaceuticals International fell $2.84 (-2.1%) to $133.35 on average volume. Throughout the day, 2,243,730 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 2,551,300 shares. The stock ranged in price between $133.08-$136.14 after having opened the day at $135.77 as compared to the previous trading day's close of $136.19. Other companies within the Health Care sector that declined today were: Cynosure ( CYNO), down 11.0%, Aoxing Pharmaceutical ( AXN), down 10.6%, Hanger ( HGR), down 10.6% and Kips Bay Medical ( KIPS), down 10.4%.

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter (OTC) products, and medical devices in the areas of eye health, dermatology, and neurology therapeutic classes worldwide. Valeant Pharmaceuticals International has a market cap of $45.5 billion and is part of the drugs industry. Shares are up 16.0% year to date as of the close of trading on Monday. Currently there are 11 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk and disappointing return on equity.

On the positive front, Sagent Pharmaceuticals ( SGNT), up 9.7%, Nanoviricides ( NNVC), up 8.2%, IsoRay ( ISR), up 8.1% and Vivus ( VVUS), up 7.2% , were all gainers within the health care sector with InterMune ( ITMN) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers